Legal & General Group PLC Cel Sci Corp Transaction History

Legal & General Group PLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$3.09 - $5.23 $96,092 - $162,642	-31,098 Reduced 92.36%	2,573 $8,000
Q2 2022 Aug 22, 2022	BUY	$2.58 - $4.99 $34,675 - $67,065	13,440 Added 66.43%	33,671 $152,000
Q1 2022 May 16, 2022	BUY	$3.93 - $7.7 $5,596 - $10,964	1,424 Added 7.57%	20,231 $79,000
Q3 2021 Nov 15, 2021	BUY	$7.64 - $12.49 $61,196 - $100,044	8,010 Added 74.19%	18,807 $207,000
Q2 2021 Aug 12, 2021	BUY	$8.68 - $27.49 $48,139 - $152,459	5,546 Added 105.62%	10,797 $93,000
Q1 2021 May 17, 2021	SELL	$12.0 - $27.64 $1,764 - $4,063	-147 Reduced 2.72%	5,251 $80,000
Q3 2020 Nov 13, 2020	SELL	$11.69 - $14.54 $15,559 - $19,352	-1,331 Reduced 19.78%	5,398 $68,000
Q2 2020 Aug 14, 2020	BUY	$9.75 - $17.6 $14,703 - $26,540	1,508 Added 28.88%	6,729 $101,000
Q1 2020 May 14, 2020	SELL	$7.54 - $17.05 $482 - $1,091	-64 Reduced 1.21%	5,221 $60,000
Q4 2019 Feb 13, 2020	BUY	$6.71 - $9.55 $6,005 - $8,547	895 Added 20.39%	5,285 $46,000
Q2 2019 Aug 14, 2019	BUY	$3.77 - $8.67 $16,550 - $38,061	4,390 New	4,390 $34,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.